Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Bimatoprost 0.03% Formulation B Ophthalmic Solution
Bimatoprost 0.03% Formulation B · 1 trial · 2 indications
Change from baseline in worse eye IOP at Week 12 . IOP is a measurement of fluid pressure inside the eye. IOP measurements in the worse eye were evaluated at hours 0, 2, and 8. A negative number change from baseline indicated a reduction in IOP, and a positive number change from baseline indicated an increase in IOP.
Average Eye IOP at Week 12 . IOP is a measurement of fluid pressure inside the eye. IOP measurements were evaluated at hours 0, 2, and 8 in both eyes and the average IOP of both eyes at each time point were reported. Baseline data are included for reference only.
Average Eye IOP at Week 6 . IOP is a measurement of fluid pressure inside the eye. IOP measurements were evaluated at hours 0, 2, and 8 in both eyes and the average IOP of both eyes at each time point were reported.
Average Eye IOP at Week 2 . IOP is a measurement of fluid pressure inside the eye. IOP measurements were evaluated at hours 0, 2, and 8 in both eyes and the average IOP of both eyes at each time point were reported.
| Arm | Type | Description |
|---|---|---|
| Bimatoprost 0.03% Formulation B Ophthalmic Solution | EXPERIMENTAL | Bimatoprost 0.03% Formulation B Ophthalmic Solution |
| Bimatoprost 0.03% Ophthalmic Solution | ACTIVE_COMPARATOR | Bimatoprost 0.03% Ophthalmic Solution |
| Name | Type | Description |
|---|---|---|
| Bimatoprost 0.03% Formulation B Ophthalmic Solution | DRUG | One drop administered in each eye, every evening, for 12 weeks |
| Bimatoprost 0.03% Ophthalmic Solution | DRUG | One drop administered in each eye, every evening, for 12 weeks |
Inclusion Criteria: * Patient has ocular hypertension or glaucoma in both eyes * Requires IOP-lowering therapy in each eye Exclusion Criteria: * Active or recurrent eye disease that would interfere with interpretation of study data in either eye * History of any eye surgery or laser in either eye...
Top 5 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Travoprost |
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | AGN-193408 |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
Bimatoprost 0.03% Formulation B is an investigational ophthalmic solution being developed by AbbVie Inc. for the treatment of glaucoma. It is a small molecule formulation of bimatoprost delivered as an eye drop. The program has completed a Phase 3 clinical trial, and the asset is not approved for marketing based on the development information available.
Bimatoprost 0.03% Formulation B is being studied for glaucoma, with the completed Phase 3 trial also enrolling patients with ocular hypertension. Glaucoma is a group of eye conditions involving elevated intraocular pressure that can damage the optic nerve. The drug is an investigational therapy and has not been established as a marketed treatment.
Bimatoprost 0.03% Formulation B targets PTGFR, the prostaglandin F receptor, and acts as an agonist at that receptor. Agonism of PTGFR in the eye is associated with increased aqueous humor outflow, which is the mechanism by which bimatoprost-class agents lower intraocular pressure in glaucoma. The drug is a small molecule ophthalmic solution.
Bimatoprost 0.03% Formulation B is developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the clinical program evaluating this ophthalmic formulation in patients with glaucoma and ocular hypertension.
Bimatoprost 0.03% Formulation B is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently listed as active. The asset is investigational, and the available development information does not indicate that it has received FDA approval for any indication.
Bimatoprost 0.03% Formulation B has been evaluated in the Phase 3 trial NCT01099774, titled Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension. The completed study enrolled 597 patients in the United States, was randomized, double blind, and used an active control.
Yes. Bimatoprost 0.03% Formulation B Ophthalmic Solution is an alternative name for Bimatoprost 0.03% Formulation B, referring to the same investigational product. Both names describe the AbbVie-developed small molecule eye drop being studied in glaucoma and ocular hypertension, so searches for either name point to the same asset.